December 14, 2021
Willkie advised Cardiovalve in its sale to Venus Medtech.
On December 7, structural heart disease treatment company Venus Medtech announced its acquisition of Cardiovalve Ltd. (f/k/a Mitraltech Ltd.), a transcatheter mitral and tricuspid valve treatment company. The deal is valued at $300 million, pending the completion of certain milestones.
Venus Medtech is a leading in heart valve disease treatment company in China. The acquisition is expected to enhance the company's product pipeline in the field of cardiac valve disease treatment and accelerate its internationalization.
Israel-based Cardiovalve has developed a transcatheter interventional replacement product for patients suffering from mitral or tricuspid regurgitation. Its treatment of mitral regurgitation has entered clinical trials in Europe and is currently in an early feasibility study in the U.S.
The Willkie team was led by partners Morgan Elwyn and Ziyad Aziz and included associates Tai Fukumoto and Brandon Harmer.
